-
SI-BONE reports preliminary Q4 revenue of $56.2-56.3 million
-
This MedTech stock was just added to Needham's Conviction List
-
SI-BONE Inc. (SIBN) PT Raised to $27 at Needham, Added To Conviction List
-
SI-BONE (SIBN) Reiterated at Overweight Post 3Q25 Results, Guidance Raise
-
Needham Reiterates Buy Rating on SI-BONE Inc. (SIBN)
-
SI-BONE Inc. (SIBN) Tops Q3 EPS by 6c, provides guidance
-
Cantor Fitzgerald Reiterates Overweight Rating on SI-BONE Inc. (SIBN)
-
SI-BONE Inc. (SIBN) PT Raised to $26 at Canaccord Genuity
-
SI-BONE Inc. (SIBN) PT Raised to $28 at Jefferies
-
SI-BONE Inc. (SIBN) Tops Q2 EPS by 4c, provides guidance
-
Cantor Fitzgerald Reiterates Overweight Rating on SI-BONE Inc. (SIBN)
-
Citizens JMP Reiterates Market Outperform Rating on SI-BONE Inc. (SIBN)
-
Needham Reiterates Buy Rating on SI-BONE Inc. (SIBN)
-
SI-BONE Inc. (SIBN) Tops Q1 EPS by 8c, provides guidance
-
Cantor Fitzgerald newsletter says Elutia best, Anteris worst performer
-
Cantor Fitzgerald Reiterates Overweight Rating on SI-BONE Inc. (SIBN)
-
SI-BONE Inc. (SIBN) PT Raised to $24 at Needham
-
SI-BONE Inc. (SIBN) Tops Q4 EPS by 4c, provides guidance
-
MedTech sector outlook for 2025: Truist Securities
-
Medical Technology and Devices: Piper Sandler Shares 'Quick Thoughts on HC Conference in Jan'
-
SI-BONE Inc. (SIBN) PT Lowered to $15 at Morgan Stanley
-
Needham Reiterates Buy Rating on SI-BONE Inc. (SIBN)
-
SI-BONE Inc. (SIBN) Tops Q3 EPS by 8c
-
SI-BONE Inc. (SIBN) Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation
-
Piper Sandler Reiterates Overweight Rating on SI-BONE Inc. (SIBN)
-
Canaccord Genuity Reiterates Buy Rating on SI-BONE Inc. (SIBN)
-
Cantor Fitzgerald Reiterates Overweight Rating on SI-BONE Inc. (SIBN)
-
SI-BONE Inc. (SIBN) Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System
-
SI-BONE Inc. (SIBN) PT Lowered to $19 at Needham
-
SI-BONE Inc. (SIBN) Tops Q2 EPS by 6c

